Early detection of Alzheimer's disease (AD) is critical for effective disease management and treatment. Web-based assessment tools offer advantages by enabling broader accessibility and reducing reliance on specialized clinical infrastructure.
Objective
This study aimed to validate a self-administered, web-based cognitive assessment tool for AD screening.
Methods
A total of 106 older adults aged 55 to 84 years were recruited and clinically classified as cognitively unimpaired (CU, n = 35), amnestic mild cognitive impairment (aMCI, n = 37), or AD (n = 34). Participants completed Cogscreen, a 10-min web-based cognitive test comprising verbal cued memory and digit symbol substitution tasks.
Results
Both the verbal cued memory and digit symbol substitution tasks showed significant score differences among CU, aMCI, and AD (p < 0.001). The Cogscreen composite score yielded area under the curve (AUC) values of 0.876 for aMCI (cut-off = 0.64, sensitivity = 0.865, specificity = 0.657) and 0.994 for AD (cut-off = −0.59, sensitivity = 0.971, specificity = 0.971), and outperformed the Mini-Mental State Examination (MMSE) in diagnosing aMCI (AUC = 0.638, p = 0.001). The composite score significantly correlated with the Consortium to Establish a Registry for Alzheimer's Disease assessment packet total score (r = 0.765, p < 0.001) and MMSE score (r = 0.722, p < 0.001).
Conclusions
Cogscreen is a rapid, self-administered cognitive screening tool for detecting aMCI and AD. It outperforms the MMSE in identifying early cognitive decline and holds potential for detecting even subtler cognitive changes in the future.
BetterMA. Alzheimer’s disease facts and figures. Alzheimers Dement2023; 19: 1598–1695.
3.
CummingsJOsseAMLCammannD, et al.Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs2024; 38: 5–22.
4.
FredricksonJMaruffPWoodwardM, et al.Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies. Neuroepidemiology2010; 34: 65–75.
5.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
6.
NasreddineZSPhillipsNABédirianV, et al.The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
7.
Proust-LimaCAmievaHDartiguesJ-F, et al.Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population–based studies. Am J Epidemiol2007; 165: 344–350.
8.
StrickerNHTwohyELAlbertsonSM, et al.Mayo-PACC: a parsimonious preclinical Alzheimer's disease cognitive composite comprised of public-domain measures to facilitate clinical translation. Alzheimers Dement2023; 19: 2575–2584.
9.
FarrellMEPappKVBuckleyRF, et al.Association of emerging β-amyloid and tau pathology with early cognitive changes in clinically normal older adults. Neurology2022; 98: e1512–e1524.
10.
PappKVRofaelHVeroffA, et al.Sensitivity of the preclinical Alzheimer’s cognitive composite (PACC), PACC5, and repeatable battery for neuropsychological status (RBANS) to amyloid status in preclinical Alzheimer’s disease-atabecestat phase 2b/3 EARLY clinical trial. J Prev Alzheimers Dis2022; 9: 255–261.
11.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
12.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Focus2013; 11: 96–106.
13.
PetersenRC. Mild cognitive impairment as a diagnostic entity. J Intern Med2004; 256: 183–194.
14.
GrandeGVanacoreNVetranoDL, et al.Free and cued selective reminding test predicts progression to Alzheimer’s disease in people with mild cognitive impairment. Neurol Sci2018; 39: 1867–1875.
15.
WechslerD. The measurement of adult intelligence. J Nerv Mental Dis1940; 91: 48.
16.
JaegerJ. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol2018; 38: 513–519.
17.
LeeJHLeeKULeeDY, et al.Development of the Korean version of the consortium to establish a registry for Alzheimer's disease assessment packet (CERAD-K) clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci2002; 57: P47–P53.
18.
MorrisJCHeymanAMohsRC, et al.The consortium to establish a registry for Alzheimer's disease (CERAD). part I. Clinical and Neuropsychological Assessment of Alzheimer's Disease. Neurology1989; 39: 1159–1165.
19.
LeeD-YLeeK-ULeeJ-H, et al.A normative study of the Mini-mental state examination in the Korean elderly. J Korean Neuropsychiatr Assoc2002; 41: 508–525.
20.
CiesielskaNSokołowskiRMazurE, et al.Is the Montreal cognitive assessment (MoCA) test better suited than the Mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol2016; 50: 1039–1052.
21.
TsoiKKChanJYHiraiHW, et al.Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med2015; 175: 1450–1458.
22.
HabibzadehFHabibzadehPYadollahieM. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med2016; 26: 297–307.
23.
R: A Language and Environment for Statistical Computing. Vienna, Austria: R Core Team, 2024.
24.
GroberEVeroffAELiptonRB. Temporal unfolding of declining episodic memory on the free and cued selective reminding test in the predementia phase of Alzheimer's disease: implications for clinical trials. Alzheimers Dement (Amst)2018; 10: 161–171.
25.
LemosRMarôcoJSimõesMR, et al.The free and cued selective reminding test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a prospective longitudinal study. J Neuropsychol2017; 11: 40–55.
26.
WilliamsonMMaruffPSchembriA, et al.Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimer’s disease. J Clin Exp Neuropsychol2022; 44: 768–779.
27.
GalvinJEToleaMIMooreC, et al.The number symbol coding task: a brief measure of executive function to detect dementia and cognitive impairment. PLoS One2020; 15: e0242233.
PappKVRentzDMOrlovskyI, et al.Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement (N Y)2017; 3: 668–677.
30.
MaassALockhartSNHarrisonTM, et al.Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci2018; 38: 530–543.
31.
KoychevIHoferMFriedmanN. Correlation of Alzheimer disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers. J Nucl Med2020; 61: 1413–1418.
32.
TidemanPStomrudELeuzyA, et al.Association of β-amyloid accumulation with executive function in adults with unimpaired cognition. Neurology2022; 98: e1525–e1533.
33.
LimHKNebesRSnitzB, et al.Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain2014; 137: 3327–3338.
34.
ChenXJuarezAMasonS, et al.Longitudinal relationships between Aβ and tau to executive function and memory in cognitively normal older adults. Neurobiol Aging2025; 145: 32–41.
35.
SpallazziMMicheliniGBaroccoF, et al.The role of free and cued selective reminding test in predicting [18F] Florbetaben PET results in mild cognitive impairment and mild dementia. J Alzheimers Dis2020; 73: 1647–1659.
36.
De SimoneMSPerriRFaddaL, et al.Predicting progression to Alzheimer’s disease in subjects with amnestic mild cognitive impairment using performance on recall and recognition tests. J Neurol2019; 266: 102–111.
37.
AllenLBakerEThorpE, et al.Validation and comparison of a digital digit symbol substitution (DSST) task performed on smart phones with a traditional paper-pencil version. Biol Psychiatry2021; 89: S132–S133.
38.
SegevORazIGersteinHC, et al.Development and first-stage validation of a digital version of the digit symbol substitution test for use in assessing cognitive function in older people with diabetes. Diabetes Obes Metab2024; 26: 3299–3305.
39.
LeeK-SCheongH-KOhB-H, et al.Comparison of the validity of screening tests for dementia and mild cognitive impairment of the elderly in a community: k-MMSE, MMSE-K, MMSE-KC, and K-HDS. J Korean Neuropsychiatr Assoc2009; 48: 61–69.
40.
Arevalo-RodriguezISmailagicNi FigulsMR, et al.Mini-mental state examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2015; 3: CD010783.
41.
DevenneyEHodgesJR. The Mini-mental state examination: pitfalls and limitations. Pract Neurol2017; 17: 79–80.
42.
Nieuwenhuis-MarkRE. The death knoll for the MMSE: has it outlived its purpose?J Geriatr Psychiatry Neurol2010; 23: 151–157.
43.
PakzadSRinguetteJBorqueP, et al.Executive functions and screening for mild cognitive impairment and Alzheimer’s disease: a cross-sectional study. Acta Psychopathol2018; 4: 15.
44.
JunqueraAGarcía-ZamoraEOlazaránJ, et al.Role of executive functions in the conversion from mild cognitive impairment to dementia. J Alzheimers Dis2020; 77: 641–653.
45.
WeissbergerGHStrongJVStefanidisKB, et al.Diagnostic accuracy of memory measures in Alzheimer’s dementia and mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev2017; 27: 354–388.
46.
KimH-GBaiD-SKooB-H, et al.Dementia overdiagnosis in younger, higher educated individuals based on MMSE alone: analysis using deep learning technology. J Korean Med Sci2025; 40: 20.
47.
BrandtJAretouliENeijstromE, et al.Selectivity of executive function deficits in mild cognitive impairment. Neuropsychology2009; 23: 07.
48.
MezJCosentinoSBrickmanAM, et al.Faster cognitive and functional decline in dysexecutive versus amnestic Alzheimer's subgroups: a longitudinal analysis of the national Alzheimer's coordinating center (NACC) database. PLoS One2013; 8: e65246.
49.
CloutierSChertkowHKergoatM-J, et al.Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment. J Alzheimers Dis2015; 47: 901–913.
50.
ClémentFBellevilleS. Compensation and disease severity on the memory-related activations in mild cognitive impairment. Biol Psychiatry2010; 68: 894–902.
51.
ArbuthnottKFrankJ. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol2000; 22: 518–528.
52.
ÖhmanFHassenstabJBerronD, et al.Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimers Dement (Amst)2021; 13: e12217.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
